0.3597
5.79%
+0.0197
After Hours:
.3401
-0.0196
-5.45%
Mustang Bio Inc stock is currently priced at $0.3597, with a 24-hour trading volume of 125.96K.
It has seen a +5.79% increased in the last 24 hours and a -66.69% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.3566 pivot point. If it approaches the $0.3819 resistance level, significant changes may occur.
Mustang Bio Inc Stock (MBIO) Financials Data
Mustang Bio Inc (MBIO) Net Income 2024
MBIO net income (TTM) was -$51.60 million for the quarter ending December 31, 2023, a +33.44% increase year-over-year.
Mustang Bio Inc (MBIO) Cash Flow 2024
MBIO recorded a free cash flow (TTM) of -$49.59 million for the quarter ending December 31, 2023, a +27.23% increase year-over-year.
Mustang Bio Inc (MBIO) Earnings per Share 2024
MBIO earnings per share (TTM) was -$6.00 for the quarter ending December 31, 2023, a +40.65% growth year-over-year.
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
GlobeNewswire Inc.
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire Inc.
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
GlobeNewswire Inc.
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
GlobeNewswire Inc.
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire Inc.
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Cap:
|
Volume (24h):